Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
Jielin LiLaura PohlJulia SchuelerNina KorzeniewskiPhilipp ReimoldAdam KaczorowskiWeibin HouStefanie ZschäbitzCathleen NientiedtDirk JägerMarkus HohenfellnerAnette DuensingStefan DuensingPublished in: Biomedicines (2021)
In this proof-of-concept study, we show that patient-individualized in vitro drug screening and preclinical validation is feasible. However, the fact that carfilzomib failed to deliver a clinical benefit in RCC patients in a recent phase II trial unrelated to the present study underscores the complexities and limitations of this strategy.
Keyphrases
- renal cell carcinoma
- drug discovery
- end stage renal disease
- case report
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cell therapy
- peritoneal dialysis
- prognostic factors
- stem cells
- multiple myeloma
- clinical trial
- mesenchymal stem cells
- patient reported
- bone marrow
- cancer therapy
- cord blood
- adverse drug
- double blind